Compare SSTK & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | ZVRA |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.9M | 664.7M |
| IPO Year | 2012 | 2015 |
| Metric | SSTK | ZVRA |
|---|---|---|
| Price | $2.20 | $8.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 901.5K | ★ 997.2K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 44.49% | N/A |
| EPS Growth | 23.76 | ★ 159.21 |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $43.81 |
| Revenue Next Year | N/A | $15.30 |
| P/E Ratio | ★ N/A | $8.83 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $2.20 | $8.01 |
| 52 Week High | $21.68 | $15.04 |
| Indicator | SSTK | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 24.82 | 35.83 |
| Support Level | N/A | N/A |
| Resistance Level | $4.67 | $9.24 |
| Average True Range (ATR) | 0.33 | 0.66 |
| MACD | -0.08 | -0.22 |
| Stochastic Oscillator | 1.24 | 0.86 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.